Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteope...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
LDT79
LDT79 May. 15 at 2:19 PM
$MREO SELL THE FUCKINg COMPANY - FIRE CEO !!!
0 · Reply
Crivit
Crivit May. 15 at 12:04 PM
$MREO https://x.com/ej23ny/status/2055006486036611268?s=46&t=bEBIliluVsTI7poV3L9h2Q
0 · Reply
Teamtalk2014
Teamtalk2014 May. 14 at 7:22 PM
$MREO Close to 41m shares acquired by Bank of America Corp. Just reported
2 · Reply
LDT79
LDT79 May. 14 at 6:48 PM
$MREO what the fuck do these people everyday to spend $1M a month? FIRE THE FUCKING CEO ALREADY !!!!!!
0 · Reply
Invest2live
Invest2live May. 14 at 5:48 PM
$RXT 1414% already in 3 months; congrats 😊🌟🌿🔆 Checkout $ARAY, $MREO as well as $AKBA; do your DD and get in. And $PHR for long. Follow for more research based stock alerts for free. Always do your DD. Let me know your favorite stocks.
1 · Reply
ParallelPort
ParallelPort May. 14 at 5:24 PM
$MREO So let us look into the voting which i was wrong on and was not unanimous. But 20% opposition is a huge positive for the stock. It means that the threat of flooding the market with currently owned shares is a strong possibility if an offering were to be announced anytime in the distant future as some current institutions will not sit and wait to be dilluted,. While the SEC filing (8-K) does not explicitly name individual shareholders in the poll results, the numbers tell a very specific story about the "motive" and "ownership" blocks: The 61.5 Million "No" Block (Resolutions 10 & 11): This block represents approximately 7.7% of the total shares outstanding (798M total). This closely aligns with the stake of Rubric Capital Management LP, which has historically been the primary activist voice in MREO. Their vote against the 150% share allotment suggests they are unwilling to give management a "blank check" for massive dilution at these multi-year lows without a confirmed partner.
1 · Reply
ParallelPort
ParallelPort May. 14 at 5:24 PM
$MREO On the share issuance votes, nearly 120 million shares were "withheld." In U.K. law, a "withhold" is a protest vote that technically allows the resolution to pass (as it doesn't count toward the % for/against) but signals deep dissatisfaction. This likely accounts for the other major "Whales" like EcoR1 Capital or 683 Capital, who may have chosen to "sit out" the vote as a warning to the board rather than voting down the authority entirely and risking a Nasdaq delisting. The Director Re-elections: Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz (the directors originally appointed via the Rubric settlement in 2022) were re-elected, but each faced about 6.2% to 6.4% opposition (~19 million "Against" votes). This suggests that while the large block (Rubric) may have supported the individuals, a significant portion of the retail or smaller institutional base is frustrated with the board's inability to close the Alvelestat deal. For this reason an offering may be withheld a while
0 · Reply
JFais
JFais May. 14 at 1:55 PM
$RARE's partner $MREO jumping the gun a bit (in a good way) Sounds like there may indeed be a path forward for setrusumab in OI in the pediatric population Regulatory interactions initiated, updates to be provided after feedback received Clear separation in the COSMIC study🧐
0 · Reply
Henry20feb_
Henry20feb_ May. 14 at 7:41 AM
$MREO As a result, Mereo itself describes setrusumab as a “>$1BN market opportunity” in OI. From a professional investor standpoint, the opportunity is attractive because even limited penetration of severe pediatric OI patients at orphan biologic pricing can generate several hundred million dollars in annual revenue. A pediatric approval alone would likely establish setrusumab as the foundational therapy in OI and create expansion opportunities into broader pediatric and adult segments over time.
0 · Reply
Henry20feb_
Henry20feb_ May. 14 at 6:52 AM
$MREO Price target rising 🚀
0 · Reply
Latest News on MREO
Mereo BioPharma sees cash runway into mid-2027

2026-01-12T13:20:17.000Z - 4 months ago

Mereo BioPharma sees cash runway into mid-2027


Largest borrow rate increases among liquid names

2026-01-08T13:45:20.000Z - 4 months ago

Largest borrow rate increases among liquid names

ABTC ARBE CPB LAES SBLK TBT USO


Mereo BioPharma downgraded to Hold from Buy at Jefferies

2025-12-30T01:50:19.000Z - 4 months ago

Mereo BioPharma downgraded to Hold from Buy at Jefferies

RARE


Mereo BioPharma price target lowered to $1 from $6 at BTIG

2025-12-29T18:40:08.000Z - 4 months ago

Mereo BioPharma price target lowered to $1 from $6 at BTIG


Mereo BioPharma Group trading resumes

2025-12-29T13:55:07.000Z - 4 months ago

Mereo BioPharma Group trading resumes


Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 1 year ago

Mereo BioPharma Provides Update on Lead Clinical Programs


LDT79
LDT79 May. 15 at 2:19 PM
$MREO SELL THE FUCKINg COMPANY - FIRE CEO !!!
0 · Reply
Crivit
Crivit May. 15 at 12:04 PM
$MREO https://x.com/ej23ny/status/2055006486036611268?s=46&t=bEBIliluVsTI7poV3L9h2Q
0 · Reply
Teamtalk2014
Teamtalk2014 May. 14 at 7:22 PM
$MREO Close to 41m shares acquired by Bank of America Corp. Just reported
2 · Reply
LDT79
LDT79 May. 14 at 6:48 PM
$MREO what the fuck do these people everyday to spend $1M a month? FIRE THE FUCKING CEO ALREADY !!!!!!
0 · Reply
Invest2live
Invest2live May. 14 at 5:48 PM
$RXT 1414% already in 3 months; congrats 😊🌟🌿🔆 Checkout $ARAY, $MREO as well as $AKBA; do your DD and get in. And $PHR for long. Follow for more research based stock alerts for free. Always do your DD. Let me know your favorite stocks.
1 · Reply
ParallelPort
ParallelPort May. 14 at 5:24 PM
$MREO So let us look into the voting which i was wrong on and was not unanimous. But 20% opposition is a huge positive for the stock. It means that the threat of flooding the market with currently owned shares is a strong possibility if an offering were to be announced anytime in the distant future as some current institutions will not sit and wait to be dilluted,. While the SEC filing (8-K) does not explicitly name individual shareholders in the poll results, the numbers tell a very specific story about the "motive" and "ownership" blocks: The 61.5 Million "No" Block (Resolutions 10 & 11): This block represents approximately 7.7% of the total shares outstanding (798M total). This closely aligns with the stake of Rubric Capital Management LP, which has historically been the primary activist voice in MREO. Their vote against the 150% share allotment suggests they are unwilling to give management a "blank check" for massive dilution at these multi-year lows without a confirmed partner.
1 · Reply
ParallelPort
ParallelPort May. 14 at 5:24 PM
$MREO On the share issuance votes, nearly 120 million shares were "withheld." In U.K. law, a "withhold" is a protest vote that technically allows the resolution to pass (as it doesn't count toward the % for/against) but signals deep dissatisfaction. This likely accounts for the other major "Whales" like EcoR1 Capital or 683 Capital, who may have chosen to "sit out" the vote as a warning to the board rather than voting down the authority entirely and risking a Nasdaq delisting. The Director Re-elections: Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz (the directors originally appointed via the Rubric settlement in 2022) were re-elected, but each faced about 6.2% to 6.4% opposition (~19 million "Against" votes). This suggests that while the large block (Rubric) may have supported the individuals, a significant portion of the retail or smaller institutional base is frustrated with the board's inability to close the Alvelestat deal. For this reason an offering may be withheld a while
0 · Reply
JFais
JFais May. 14 at 1:55 PM
$RARE's partner $MREO jumping the gun a bit (in a good way) Sounds like there may indeed be a path forward for setrusumab in OI in the pediatric population Regulatory interactions initiated, updates to be provided after feedback received Clear separation in the COSMIC study🧐
0 · Reply
Henry20feb_
Henry20feb_ May. 14 at 7:41 AM
$MREO As a result, Mereo itself describes setrusumab as a “>$1BN market opportunity” in OI. From a professional investor standpoint, the opportunity is attractive because even limited penetration of severe pediatric OI patients at orphan biologic pricing can generate several hundred million dollars in annual revenue. A pediatric approval alone would likely establish setrusumab as the foundational therapy in OI and create expansion opportunities into broader pediatric and adult segments over time.
0 · Reply
Henry20feb_
Henry20feb_ May. 14 at 6:52 AM
$MREO Price target rising 🚀
0 · Reply
ParallelPort
ParallelPort May. 13 at 11:30 PM
$MREO Hoping something really good comes out of tomorrow for you all 🤞
2 · Reply
Henry20feb_
Henry20feb_ May. 13 at 8:57 PM
$MREO Mereo BioPharma Group delivered a materially stronger update than the market anticipated. The decision by Mereo and Ultragenyx Pharmaceutical to initiate regulatory discussions confirms continued confidence in a pediatric approval pathway. Importantly, management also tightened operating spend, reduced quarterly net loss substantially, and maintained cash runway into mid-2027. At the same time, alvelestat remains Phase 3-ready with active partnering discussions underway, while the partnered vantictumab program continues advancing without meaningful cash burden to Mereo. Overall, the company retains multiple credible value drivers with near-term regulatory and business development catalysts ahead.
0 · Reply
GangsterX
GangsterX May. 12 at 6:18 PM
$MREO added .25 ... small bet
1 · Reply
ParallelPort
ParallelPort May. 12 at 2:39 PM
$MREO My current read on the report-nothing new besides some communication on moving Sestrunab forward which looks like end of year at best, and at a much reduced clinical value. Same talk on Alvelestat as always with nothing new. With Prop 10 pretty guaranteed to pass and no reasoning for it in this report there is nowhere to go but down then an ADS split. There is a small chance they say something Thurday that wasn't said today. I stored posting darkpool, shirt interest etc. because at this point it's not relevant. Hope I'm wrong, and i wish you all luck.
2 · Reply
Henry20feb_
Henry20feb_ May. 12 at 1:01 PM
$MREO The totality of evidence still supports approval of Setrusumab in pediatric OI (actively pursued) / FDA/EMA discussions are already underway rather than merely planned / Commercial/manufacturing scaled back (conservative) / Cashburn improved - dilution pressure reduced etc.
0 · Reply
GamblingFerret
GamblingFerret May. 12 at 12:45 PM
$MREO Mereo and Ultragenyx finalyzed data analysis and initiated engagement with FDA and EMA for possible way forward in pediatric population. The asset is alive, great news! Check especially slide 25 of the updated coporate deck. Sounds like Alvelestat deal is also close to the finish line. https://www.mereobiopharma.com/news/mereo-biopharma-reports-first-quarter-2026-financial-results-and-provides-corporate-updates/ https://www.mereobiopharma.com/media/cxeh3dlw/mereo-corporate-presentation.pdf#1
0 · Reply
MaxPain_Trader
MaxPain_Trader May. 11 at 7:52 PM
$MREO a penny stock worth going ALL IN
1 · Reply
Dracula88
Dracula88 May. 11 at 7:18 PM
$MREO 🚀
0 · Reply
Teamtalk2014
Teamtalk2014 May. 11 at 2:53 PM
$MREO - Proposal 10 AGM (this week will provide alot of insight to see if the below thesis is in play. The options grant structures from Feb 26, low execution prices and the static nature of the company and the silence from Rubric despite the vast drop in share price considering the 22 proxy battle, could be leaning this way.
1 · Reply
ParallelPort
ParallelPort May. 11 at 4:27 AM
$MREO Nothing technical here, just opinion. I think this is the week you all get a semi- conclusion to where MREO is going. Unless something was announced earlier this evening i just have not looked into yet, i would not be so certain for a ER, which could be telling before the AGM Thurday. Best case scenario ER on Wed explaining positive reasons for Prop 10 vote on thurs like finding alvelstat partnering and ready to move forward, which is a string possibility. Without an ER and just a Prop 10 passing without reason this thing is headed south of .20 quick. Either way, something should give this week.
0 · Reply
JFais
JFais May. 9 at 6:18 PM
$RARE (L), $MREO (NP) The curious case of setrusumab... per Q1 call:
0 · Reply
grod86
grod86 May. 8 at 6:33 PM
$MREO DSK is a fireside chatter. Fire the CEO.
1 · Reply